Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
Authors: Punnee Pitisuttithum
Phillip W. Berman
Benjaluck Phonrat
Pravan Suntharasamai
Suwanee Raktham
La Ong Srisuwanvilai
Krit Hirunras
Dwip Kitayaporn
Jaranit Kaewkangwal
Sricharoen Migasena
Haynes W. Sheppard
Elizabeth Li
Marlene Chernow
Michael L. Peterson
Riri Shibata
William L. Heyward
Donald P. Francis
Mahidol University
VaxGen, Inc.
Bangkok Metropolitan Administration
Viral Rickettsial Disease Laboratory
Novacea, Inc.
Gilead Sciences Incorporated
Keywords: Medicine
Issue Date: 1-Sep-2004
Citation: Journal of Acquired Immune Deficiency Syndromes. Vol.37, No.SUPPL. 1 (2004), 1160-1165
Abstract: A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.
ISSN: 15254135
Appears in Collections:Scopus 2001-2005

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.